1. Dampak anggaran
| Tahun | Cakupan | Pasien diobati | Tambahan belanja | Kumulatif |
|---|---|---|---|---|
| Tahun 1 | 5% | 400.000 | -Rp 53,3 miliar | -Rp 53,3 miliar |
| Tahun 2 | 15% | 1.200.000 | -Rp 248,6 miliar | -Rp 302,0 miliar |
| Tahun 3 | 30% | 2.400.000 | -Rp 705,9 miliar | -Rp 1,0 triliun |
| Tahun 4 | 50% | 4.000.000 | -Rp 1,6 triliun | -Rp 2,6 triliun |
| Tahun 5 | 70% | 5.600.000 | -Rp 3,0 triliun | -Rp 5,5 triliun |
Indonesia adults ~190 million x hypertension prevalence 31.6% (SKI 2023) ~60 million; treated ~23.4% (Riskesdas 2018) ~14 million; ACEi-treated puskesmas subset eligible to switch from captopril ~8 million (estimate; needs Fornas dispensing validation).
2. Kapasitas layanan
Uraian berikut tersedia dalam bahasa Inggris.
| Dimensi | Penilaian dan bukti |
|---|---|
| Workforce and competency capacity | The tier that would deliver the switch is the one that is adequately staffed, and the tier the current listing depends on is not. General practitioner density stands at 1.59 times the benchmark norm, while the referral cadres the hospital-exclusive listing routes through sit below it: internists at 0.87, cardiologists at 0.57 and registered nurses at 0.36. Supply is also unevenly placed rather than uniformly short, at 107.9 general practitioners per 100,000 in city districts against 31.3 in non-city districts.
|
| Diagnostic and monitoring capacity | Blood pressure measurement and follow-up are already delivered at national scale, so the switch adds no new diagnostic requirement. 2,957 of 3,275 registered hospitals provide a hypertension service, covering 88.5 per cent of districts and 97 per cent of the population. Primary-tier density is thinner and uneven: 10,338 Puskesmas, one per 6,419 adults with hypertension, ranging from 9.8 per 100,000 in Jawa to 29.9 in Sulawesi.
|
| Medicine supply and procurement capacity | The molecule is domestically manufactured and procurable today. Twenty-four registered products are active, from five Indonesian registrants, with the most recent registration dated 19 November 2025, and four stock keeping units carry a catalogue price. The constraint is not this medicine but the primary-tier basket around it: only 6 of the 30 WHO essential antihypertensives, 20 per cent, are available at the primary tier.
|
| Storage and cold-chain capacity | Not applicable to this product. Ramipril is a 5 mg oral tablet stored at room temperature; it introduces no cold chain, no controlled temperature transport and no additional storage requirement beyond the dry store every dispensing point already operates for the incumbent captopril tablet. This dimension is recorded as not applicable rather than assessed, because there is no capacity to measure, not because measurement is outstanding.
|
| Referral and shared-care capacity | The referral architecture the medicine sits behind today is exactly what the decision proposes to change. The Fornas record lists it false at the primary tier and true at the referral tier, with a chronic-refill flag already set and a maximum of 30 tablets a month. The referral tier that arrangement depends on is thin: 38.7 per cent of districts have no cardiologist, 84 per cent have no Sp.KKLP, and the skill mix runs 83.6 general practitioners to each cardiologist.
|
| Information and reporting-system capacity | The instruments needed to carry a listing change and to monitor it exist and are documented. ARC's policy review identifies 22 hypertension and non-communicable disease regulations, of which 7 are national instruments and 8 are key national control instruments, drawn from a corpus of 12,454 regulations, alongside 3 clinical guideline and consensus documents. The chronic refill register the molecule already carries is the operational record a monitored rollout would read.
|
3. Kesiapan implementasi
Uraian berikut tersedia dalam bahasa Inggris.
| Dimensi | Penilaian dan bukti |
|---|---|
| Clinical pathway and eligibility definition | The pathway change is the decision itself, not a precondition of it. The Fornas record lists ramipril false at the primary tier and true at the referral tier, with the chronic refill flag set and a maximum of 30 tablets a month. Moving the listing to the primary tier is a formulary substitution within a class already prescribed there, not a new indication or a new population. Three clinical guideline and consensus documents cover hypertension and would carry the change.
|
| Training, supervision, and escalation protocol | Supervision, not prescribing skill, is the thin part. The prescriber cadre is already in place at 83.6 general practitioners per cardiologist and 1.4 nurses per general practitioner, and the class is familiar. What is missing is the primary-care specialist cadre that would supervise a pathway change: 84 per cent of districts have no Sp.KKLP. Headcount also overstates presence, since one clinician may hold several practice licences, at 1.5 licences per general practitioner and 2.5 per cardiologist.
|
| Procurement and distribution readiness | Procurement is already in place and does not have to be built. Four stock keeping units carry a catalogue price at a median of 398 rupiah a tablet, supplied by five domestic registrants across 24 active registrations. Nationally 78 per cent of Fornas antihypertensives carry an active catalogue listing, so this molecule sits inside the normal procurement route rather than beside it.
|
| Patient education and adherence support | Adherence is the mechanism the whole case rests on, and it is the input with the best evidence behind it. Days covered run 91.4 per cent on once-daily dosing against 83.2 per cent on two to three times daily, a difference of 8.2 percentage points with an interval of 4.0 to 18.0. The Indonesian dispensing measurement enters this as a coverage effect of 0.59, interval 0.41 to 0.86, rather than as a claim about the molecule.
|
| Safety surveillance and stewardship | Both arms are ACE inhibitors, so the safety question is a shift within a class rather than exposure to a new one, and the adverse event profile is represented once in the model through the cough, taste disturbance and rash block rather than folded into adherence. Stewardship capacity for the complication that matters most is narrow: the renal-hypertension subspecialty reaches 13.6 per cent of districts, and 47.2 per cent of hypertension spending already sits in hypertensive heart disease.
|
4. Kesetaraan dan geografi
Uraian berikut tersedia dalam bahasa Inggris.
| Dimensi | Penilaian dan bukti |
|---|---|
| Province and district variation | Control is distributed far more unequally than treatment, which is what makes this a targeting question and not only a coverage one. Across 514 districts the top decile reaches 11.44 per cent control against 1.03 per cent in the bottom, a ratio of 11.1, while treatment spans only 3.3-fold. Provinces run from 2.1 per cent in Papua Pegunungan to 13.19 in Sulawesi Utara. Thirty per cent of the variation sits between provinces rather than within them.
|
| Urban, rural, remote, and island access | Living outside a city is associated with lower control after adjustment for workforce, facilities, insurance and age. The standardised coefficient for a non-city district is -0.313 standard deviations, with a 95 per cent interval of -0.585 to -0.04 that excludes zero. The unadjusted cascade agrees: 2.8 per cent of rural adults with hypertension are at target against 5.5 per cent urban, and rural treatment runs 18.8 against 25.2 per cent.
|
| Socioeconomic and PBI status | The gradient runs the wrong way for the poorest, and it opens at diagnosis rather than at the tablet. The poorest fifth reach 2.8 per cent control against 7.6 per cent in the richest, a 2.7-fold gap, while prevalence is slightly higher among the poorest at 33.0 against 30.7 per cent. Insurance coverage predicts treatment, standardised coefficient 0.113 with an interval of 0.027 to 0.199, but not control, where the interval crosses zero. Subsidised members are 41.9 per cent of the insured hypertension cohort.
|
| Age and life-course distribution | Burden rises steeply with age while control does not keep pace, so the absolute number of uncontrolled older adults is where the switch would act. Prevalence reaches 44.8 per cent at ages 50 to 59 and 56.1 per cent at 60 to 69, against control of only 5.1 and 6.5 per cent. District median age is positively associated with control, 0.231 standard deviations with an interval of 0.127 to 0.336, which is consistent with older populations being in contact with care rather than with age protecting anyone.
|
| Sex and gender distribution | Women carry more of the disease and more of the treatment, and the two arms of the cascade nearly converge at the end. Prevalence is 35.6 per cent among women against 27.5 among men, diagnosis 30.5 against 20.8, treatment 26.4 against 17.8, but control 4.8 against 4.0. So women are far more likely to be in care and only slightly more likely to be at target, which means the loss between treatment and control is larger for women in absolute terms.
|
| Disability and comorbidity distribution | Uncontrolled hypertension has already become organ damage in a large share of the treated population, which is the group the switch is meant to keep out of hospital. Hypertensive heart disease, ICD I11, accounts for 47.2 per cent of national hypertension spending, against essential hypertension alone. Severe cases are 12.7 per cent of inpatient visits. Access to the subspecialty that manages renal complication is narrow, reaching 13.6 per cent of districts.
|